---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-030392"
form_type: "8-K"
ticker: "SNDX"
cik: "0001395937"
company_name: "Syndax Pharmaceuticals Inc"
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T17:16:47.643028+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Syndax Q4 Revuforj revenue $7.7M; net loss $94.2M; cash $692.4M

## Summary
- Q4 2024 Revuforj net product revenue $7.7M in first five weeks of U.S. launch.
- Net loss $94.2M ($1.10/share) for Q4 2024 vs $72.5M ($1.00) in Q4 2023; full year net loss $318.8M ($3.72).
- Cash, equivalents and investments $692.4M; expects current resources to fund to profitability.
- Launched Niktimvo in Jan 2025 with Incyte; $350M royalty funding from Royalty Pharma on Niktimvo sales.
- sNDA for revumenib in R/R mNPM1 AML expected Q2 2025 based on positive AUGMENT-101 data.

## SEC filing metadata
- accession: 0000950170-25-030392
- form_type: 8-K
- ticker: SNDX
- cik: 0001395937
- company_name: Syndax Pharmaceuticals Inc
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1395937/000095017025030392/0000950170-25-030392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1395937/000095017025030392/sndx-20250303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-030392
- JSON: https://secwatch.observer/filing/0000950170-25-030392.json
- Plain text: https://secwatch.observer/filing/0000950170-25-030392.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.